Red light therapy and Hashimoto's thyroiditis: what the evidence shows

The thyroid problem that medication does not fully solve

Hashimoto's thyroiditis is the most common autoimmune thyroid condition in the world and the leading cause of hypothyroidism in iodine-sufficient countries. The immune system misidentifies thyroid tissue as a threat and attacks it, causing progressive inflammation and, over time, reduced hormone production. The standard treatment is levothyroxine - a synthetic form of T4 - taken daily, often for life.

For many people, that works well enough. TSH normalises on a blood test, the doctor is satisfied, and the prescription is renewed. But a significant portion of Hashimoto's patients continue to feel unwell despite normal-looking labs. Fatigue, brain fog, weight changes, low mood, and difficulty regulating temperature persist - because the underlying autoimmune attack on the thyroid gland is still happening. Levothyroxine replaces a hormone but does not address the immune process causing the damage in the first place.

That gap - between "your levels look fine" and "I still feel terrible" - is where the interest in photobiomodulation (red and near-infrared light therapy applied to tissue to stimulate cellular repair - sometimes shortened to PBM) for thyroid health comes from. And unlike many areas where the enthusiasm outpaces the science, the thyroid research here is unusually solid. There are multiple peer-reviewed clinical trials, an RCT (a randomised controlled trial - the gold standard study design, where participants are randomly assigned to treatment or placebo and do not know which group they are in) with a six-year follow-up, a 350-patient observational study, and a growing body of mechanistic evidence explaining why the effect is plausible. This is worth looking at carefully.

Why the thyroid is a good target for near-infrared light

Most organs are inaccessible to light-based therapy - they sit too deep in the body for photons to reach them. The thyroid is different. It sits just below the skin at the front of the neck, close enough to the surface that near-infrared light can penetrate to thyroid tissue without needing a specialised delivery device. That anatomical fact is what makes photobiomodulation practical for thyroid applications in a way it cannot be for, say, the liver or kidneys.

The proposed mechanism follows the same pathway as in other tissues. Near-infrared light - particularly in the 820-850 nm range used in the thyroid trials - is absorbed by cytochrome c oxidase, a protein inside the mitochondria (the cell's energy-generating structures) that drives cellular energy production. When this enzyme absorbs light, it increases ATP output (the cell's primary fuel molecule) and triggers a cascade of downstream effects: better cellular energy, reduced oxidative stress (a damaging accumulation of reactive molecules that impairs cell function), modulated inflammatory signalling, and improved local blood flow.

For a gland under chronic autoimmune attack, those effects are directly relevant. The immune cells driving the inflammation in Hashimoto's - primarily lymphocytes that have infiltrated the thyroid tissue - respond to changes in the local inflammatory environment. By shifting the balance away from pro-inflammatory signalling and towards repair, photobiomodulation may help calm immune activity, support follicular cell function (the hormone-producing cells that form the gland's secretory sacs), and improve the gland's ability to produce hormone. The 2014 TGF-beta1 study from Hofling's group found that LLLT (low-level laser therapy, the clinical term used in the earlier research) significantly increased serum TGF-beta1 - a cytokine that suppresses autoimmune activity - compared with placebo, pointing to a specific immune mechanism that would explain the clinical findings.

What the clinical evidence actually shows

The trial record on photobiomodulation for autoimmune thyroid disease is more substantial than most people realise. It starts with a Brazilian research group at the University of Sao Paulo, led by Dr Danilo Hofling, who spent over a decade systematically building an evidence base from pilot study through to long-term follow-up.

Their 2010 pilot study (15 patients with CAT-induced hypothyroidism - CAT is chronic autoimmune thyroiditis, another name for Hashimoto's - 830 nm, twice weekly for five weeks) showed that every participant reduced their levothyroxine requirement. Seven of the fifteen - nearly half - needed no levothyroxine at all through the nine-month follow-up. Anti-TPO antibody levels (the main blood marker of Hashimoto's autoimmunity) fell significantly. Thyroid tissue echogenicity - a measure of how healthy the gland's internal structure looks on ultrasound (healthy, intact tissue reflects sound waves more cleanly than inflamed or damaged tissue) - improved, suggesting partial restoration of the gland's hormone-producing architecture.

That pilot led to a randomised, placebo-controlled trial, published in Lasers in Medical Science in 2013. Forty-three patients were randomised to receive either 10 sessions of 830 nm laser therapy or a placebo treatment, twice weekly over five weeks. The difference in levothyroxine requirement nine months later was striking: the treatment group needed an average of 38.59 mcg/day, compared with 106.88 mcg/day in the placebo group - a difference that was highly statistically significant (p<0.001). Lower anti-TPO antibodies and improved thyroid echogenicity were also found in the treatment group.

The same cohort was reassessed six years later, in a 2018 follow-up study. The LLLT group still required significantly less levothyroxine than the placebo group (p=0.002). On the safety question of thyroid nodules - a relevant concern, since Hashimoto's patients have an elevated baseline risk of nodule development - nodule rates did not differ significantly between the laser and placebo groups at six years. Where nodules were found in the laser group, all were classified as Bethesda II: benign and non-suspicious. No malignant nodules were identified in either group.

A 2020 study by Ercetin et al. from Istanbul brought a much larger sample. Three hundred and fifty Hashimoto's patients were divided into two groups: one receiving photobiomodulation (850 nm) with dietary supplements (vitamin D, iron, selenium), the other receiving supplements only. The PBM group showed significantly greater increases in T3 levels and the T3/T4 ratio - a meaningful distinction, because many hypothyroid patients on standard levothyroxine therapy have low T3 relative to T4, which may explain persistent symptoms despite normal TSH. Anti-TPO antibody levels fell more in the PBM group, and levothyroxine requirements were reduced.

A 2023 clinical feasibility trial published in the Journal of Personalized Medicine (Berisha-Muharremi et al.) examined 74 women with Hashimoto's thyroiditis, comparing photobiomodulation at 820 nm combined with supplements against supplements alone. The PBM group showed significant reductions in TSH, anti-TPO antibodies, anti-TG antibodies, and levothyroxine dose requirements over a six-month follow-up. For the first time in this body of research, the authors also documented improvements in body weight, BMI, waist and hip circumference in the PBM group - a relevant finding given that weight management is one of the most common and frustrating symptoms for people with Hashimoto's.

The T3/T4 ratio: why it matters and what the research found

Most people with Hashimoto's who are medicated receive levothyroxine, which is a synthetic form of T4. The body is supposed to convert T4 into T3 - the more biologically active form - as needed. In practice, that conversion is often impaired: chronic inflammation, nutrient deficiencies, and poor mitochondrial function can all blunt the conversion process, leaving patients with normal T4 and TSH on a blood test but low functional T3.

This is thought to be one of the main reasons why some people continue to feel hypothyroid despite ostensibly normal labs. T3 is what the brain, heart, and muscles actually use - and if T4 is not converting efficiently, the downstream effects persist regardless of what the TSH number says.

The Ercetin 2020 study found that photobiomodulation improved the T3/T4 ratio significantly compared with supplements alone. The mechanism proposed is that near-infrared light, by improving mitochondrial function and reducing oxidative stress, supports the deiodinase enzymes responsible for T4-to-T3 conversion (deiodinase enzymes are proteins that convert T4 into T3 by removing an iodine atom - they are particularly sensitive to inflammation and poor cellular energy, which is why the conversion process breaks down in many Hashimoto's patients). Whether this translates to measurable symptom improvement in every patient is not yet established, but the biochemical finding is consistent with the proposed mechanism and with the subjective experience many Hashimoto's patients report after treatment.

The autoimmune angle: what happens to antibodies

In Hashimoto's thyroiditis, the immune system produces antibodies against the thyroid gland - most commonly anti-TPO (antibodies against thyroid peroxidase, an enzyme the thyroid uses to make hormone; when the immune system attacks this enzyme, it interferes with hormone production) and anti-TG (antibodies against thyroglobulin, a protein that stores thyroid hormone inside the gland). These are the markers used to diagnose the condition and monitor its severity. High antibody levels indicate an active immune attack; lower levels generally suggest the autoimmune process has calmed.

Across the photobiomodulation trials, anti-TPO antibodies fell consistently in the treatment groups compared with controls. In the Hofling 2013 RCT, TPOAb levels were significantly lower in the laser group at nine months. In the Ercetin 2020 study, anti-TPO reduction was significantly greater in the PBM plus supplements group. The 2023 Berisha-Muharremi trial found significant reductions in both anti-TPO and anti-TG antibodies in the PBM group at six months, compared with supplements only.

This is clinically significant because conventional treatment - levothyroxine - does not reduce antibody levels. It replaces the hormone but leaves the autoimmune process intact. If photobiomodulation genuinely reduces the autoimmune attack, it is doing something that standard treatment cannot.

The inflammation connection

Hashimoto's is fundamentally an inflammatory disease. Lymphocytes infiltrate the thyroid gland, release pro-inflammatory cytokines, and progressively destroy follicular cells - the specialised cells responsible for manufacturing T3 and T4. Over time, the gland becomes smaller and less functional. This inflammatory process is what drives both the elevated antibody levels and the tissue damage seen on thyroid ultrasound.

Photobiomodulation's well-documented anti-inflammatory effects operate primarily through the NF-kB pathway - NF-kB (nuclear factor kappa B) is essentially a molecular on/off switch inside cells that, when activated, triggers the production of inflammatory signalling proteins throughout the body. Near-infrared light appears to turn this switch down, calming the local immune environment in the tissue being treated. Applied directly over the thyroid gland at the neck, this is directly relevant to the autoimmune process happening there.

The TGF-beta1 finding from the Hofling group adds further specificity. TGF-beta1 (transforming growth factor beta-1) is a signalling protein that acts as a natural brake on autoimmune activity - it tells the immune system to stand down and promotes tolerance towards the body's own tissue, which is exactly what Hashimoto's patients need more of. The fact that light therapy measurably raised TGF-beta1 levels in the bloodstream provides a plausible biological mechanism for the clinical findings across the other trials: the light is not just having a vague anti-inflammatory effect, it appears to be activating a specific calming pathway directly relevant to autoimmune control.

This also connects to the fatigue picture that dominates the lived experience of Hashimoto's. Chronic inflammation is metabolically expensive and has direct effects on energy levels, cognitive clarity, and mood. The link between systemic inflammation and low mood is now well-established, and many of the subjective improvements reported by Hashimoto's patients using photobiomodulation - better energy, clearer thinking, improved mood - may partly reflect a reduction in that overall inflammatory burden rather than thyroid-specific effects alone.

What the evidence does and does not support

The honest summary of the photobiomodulation research on Hashimoto's thyroiditis is this: it is more convincing than the evidence base for most complementary approaches to thyroid disease, but it is not yet sufficient to change clinical practice on its own.

What the evidence supports: a consistent signal across multiple clinical studies that photobiomodulation at 820-850 nm, applied directly over the thyroid gland, reduces levothyroxine requirements, lowers anti-TPO antibodies, and improves the T3/T4 ratio in people with autoimmune-driven hypothyroidism. The reduction in levothyroxine dose persists at least six years. The treatment appears safe, with no adverse effects reported across the trial record and no greater rate of thyroid nodule development in the light therapy group compared with placebo. The 2022 review published in Journal of Lasers in Medical Sciences concluded that "besides current treatment strategies, LLLT could be a promising therapeutic approach for the treatment of autoimmune thyroid disease."

What the evidence does not support: replacing levothyroxine therapy. Every trial was conducted as an adjunct to standard treatment, not as a replacement. No study has shown that photobiomodulation alone can sustain euthyroid status without medication in most patients. The antibody reduction seen in the short-term trials did not persist long-term without repeat treatment. And the largest study (Ercetin 2020, 350 patients) was observational rather than randomised, which limits what can be concluded about causation.

What a practical protocol looks like

The clinical trials consistently used near-infrared wavelengths in the 820-850 nm range, applied directly over the thyroid gland at the front of the neck. Sessions were short - typically around 40 seconds to a few minutes of direct application per point - and were delivered twice weekly over periods of three to five weeks. The Hofling trials used clinical-grade laser devices; the 2023 Berisha-Muharremi feasibility trial also used a Class 3b laser device at 820 nm with a lower fluence protocol.

For someone using a full-body panel, the most direct approach is to position the panel so that the neck area receives exposure during normal sessions. Full-body panels covering the 630-660 nm red light and 810-850 nm near-infrared ranges will deliver the relevant wavelengths to thyroid tissue when the front of the neck is exposed - the gland sits close enough to the skin's surface that penetration is not a significant limitation.

The body-wide anti-inflammatory effects of near-infrared exposure across the whole body are also relevant here, even if they work through a different route than direct thyroid application. Reducing total inflammatory load throughout the body eases some of the burden on a thyroid gland that is already under attack - similar to the way that improving sleep quality and reducing inflammatory markers can improve thyroid symptoms indirectly.

The Berisha-Muharremi 2023 trial - which combined photobiomodulation with selenium and vitamin D supplementation - also showed improvements in body composition alongside thyroid markers. The combination of light therapy with targeted nutritional support may work better together than either alone, though the trial design means it is impossible to say how much of the effect came from each component.

What Hashimoto's patients are actually looking for

The population living with Hashimoto's thyroiditis is large - it affects an estimated one in ten women over the course of a lifetime, with a much lower but still significant rate in men. It is also a group that is frequently underserved by conventional medicine: told their labs are fine, their medication dose is correct, and that the persistent symptoms they are experiencing are not thyroid-related.

That gap has historically been filled by unproven interventions, detox protocols, and thyroid-specific elimination diets of variable evidence quality. Photobiomodulation is genuinely different. The evidence base is peer-reviewed, published in indexed medical journals, includes a randomised controlled trial with six-year follow-up, and the proposed mechanisms are biologically plausible and consistent with what is known about light therapy and autoimmune disease more broadly.

It is not a cure. It does not work for everyone. The effects appear to be time-limited without repeat treatment cycles. But as a low-risk, non-invasive complement to standard thyroid management - particularly for people who are medicated but still symptomatic - the clinical case is more substantial than for most of what is marketed to this community.